Effectiveness and Safety of Probiotic in Regulating Chronic Constipation
Efficacy and Safety of Probiotic BLa80 in Modulating Bowel Habits in Subjects With Chronic Constipation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Barcelona, Spain
- CAP Can Bou Castelldefels and CAP Corbera de Llobregat
-
Barcelona, Spain
- Family and Community Medicine CAP Roger
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
Patients with chronic constipation (duration more than 3 months with less than three bowel movements per week and/or Bristol Scale 1 and 2).
Exclusion Criteria:
- Diabetic patients.
- Pregnant patients.
- Breastfeeding patients.
- Patients requiring antibiotic treatment.
- Patients requiring treatment with tricyclic antidepressants, antiepileptics, antihistamines, antiparkinsonians, antipsychotics, antispasmodics, verapamil, monoamine oxidase inhibitors, opiates, sympathomimetics, antacids (with aluminum and calcium), antidiarrheals and nonsteroidal anti-inflammatory drugs.
- Patients who change the type of diet during the study.
- Patients with allergy or intolerance to any of the ingredients in the formulation of the product under study.
- Subjects with a history of pharmacological, alcoholic, or other substance abuse, or other factors that limit their ability to cooperate during the study.
- Excessive alcohol consumption (>3 glasses of wine or beer/day).
- Subjects whose condition does not make them eligible for the study, according to the researcher.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Probiotic group
2B CFU/capsule/day BLa80, before meals; Storage: Store in a cool, dry place without sun exposure.
|
The experimental phase of this study had last 84 days, and each patient will make 4 visits (d1, d28, d56, d84).
|
|
Placebo Comparator: placebo
Maltodextrin, one capsule/day, before meals; Storage: Store in a cool, dry place without exposure to the sun.
|
Placebo
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
changes in fecal state
Time Frame: 84 days
|
use Bristol Scale to record the type of fecal state
|
84 days
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Study Chair: METHODEX SL, Methodex
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- WK2023003
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Constipation
-
NCT07386795Not yet recruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation
-
NCT07387952RecruitingChronic Constipation | Constipation - Functional | Fecal Microbiota Transplantation (FMT)
-
NCT07603414Active, not recruitingChronic Constipation | Functional Constipation | Pelvic Floor | Biofeedback | Diaphragmatic Breathing
-
NCT00391820Completed
-
NCT06427863Not yet recruiting
-
NCT02425722Completed
-
NCT02809105CompletedChronic Constipation
-
NCT06621160Completed
-
NCT06526767RecruitingChronic Functional Constipation
-
NCT01523184CompletedChronic Constipation | Functional Constipation
Clinical Trials on Placebo
-
NCT03827590UnknownAcute Bronchitis | Acute Upper Respiratory Tract Infection
-
NCT02177513Completed
-
NCT06767540Not yet recruiting
-
NCT02935712CompletedMale Subjects With Type II Diabetes (T2DM)
-
NCT03198624CompletedPharmacokinetics | Safety Issues
-
NCT02982187CompletedPulmonary Disease, Chronic Obstructive
-
NCT04693039Completed
-
NCT01610388Completed
-
NCT04388215UnknownHypertension | Dyslipidemias